The U.S. FDA approved doputamine on July 23, 2002. It is an inotropic agent that helps to change the contraction force of the heart.

Dobutamine is used for cardiac patients with decreased cardiac output. It is used to treat heart failure and heart attack in patients. It is involved in the constriction of  the blood vessels, which helps to treat people who have low blood pressure. It may be administered by cardiac surgeon during open surgery in order to recover low cardiac output at surgery.

Doputamine is administered by intravenous infusion ideally by doctor or nurse. It is available as syringes in different doses such as 50 mg per ml, 200 mg per ml and 250 mg per ml. Your doctor will decide the dose, route of administration, and frequency based on your disease condition and other factors.

The common side effects that are experienced while you are on the treatment with dobutamine Injection are chest pain, feel sick, headache, fever, inflammation of the injected site, inhibited blot clot formation. If you experience any allergic reactions such as swelling hand, face and feet, lips after taking this injection, report to your doctor immediately.

Inform your doctor if you have high blood pressure and cardiac related problems. Dobutamine Injection is actively involved in stimulating the heart muscles and constriction of the blood vessels. The medication has not been given to expectant mothers, and it should only be used in situations when the projected advantages clearly outweigh any possible hazards to the foetus.

Consult your doctor if you are planning to get pregnant or think you may be pregnant while breastfeeding. Inform your doctor if you feel any joint pain or any undesirable symptoms during the medication. Patients with abnormal thickening of the left ventricle (idiopathic hypertrophic subaortic stenosis) and hypersensitive may inform the doctor before administering dobutamine Injection.

Dobutamine should only be used under the close supervision of medical professionals with access to facilities for frequent, intensive monitoring of cardiovascular and renal parameters. It is not recommended for patients with cardiac problems. Elderly patients need close monitoring of blood pressure and other clinical testing.

1. Hameln Pharma Ltd, Electronic medicines compendium (EMC), [Revised on February 2022] [Accessed on Sep2023], https://www.medicines.org.uk/emc/files/pil.6270.pdf
2. Hospira Healthcare Corporation, US Food and Drug Administration, [Accessed on 15th Jan 2022], DOBUTamine - Accessdata.fda.gov
3. KD Tripathi, Essentials of Medical Pharmacology, Adrenergic system and drugs, 7th edition, 2013,134.
4. Robert R.Ruffolo, JR; Review: The Pharmacology of Dobutamine; Published on October 1987; Accessed on 06/09/2023; https://pubmed.ncbi.nlm.nih.gov/3310640/.

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.